FDA greenlights rare blood cancer drug Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 31 August, 2026

For 15 years, Rock Health Summit has brought together founders, clinicians, investors, and enterprise leaders at the intersection of healthcare and technology. Come be a part of it—and meet your next customer or collaborator—with 10% off using discount code EPN-RHS-2026. sponsored by Rock Health

presented by How the Riyadh Glob­al Med­ical Biotech­nol­o­gy Sum­mit is de-risk­ing Sau­di Ara­bi­a's cell and gene ther­a­py am­bi­tions

news AstraZeneca's relaxin pill shows promise in mid-stage heart failure trial FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder Novartis pushes ahead with its IL-6 inhibitor despite Novo's failure

Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable Sep 10 11:00 am ET Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence sponsored by Cellares Sep 16 2:00 pm ET Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data sponsored by GeneDx Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

More from #ESC26 Data in hand, Cytokinetics looks to expanded Myqorzo approval CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy Future of AstraZeneca’s gene silencer in heart disease uncertain after trial failure

in case you missed it 1. BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine 2. Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance 3. Peer Review Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO 4. Roivant’s road to a potential blockbuster begins with FDA approval for Lisraya 5. Gilead gets another HIV treatment approval, extending lenacapavir's dominance 6. News Briefing Mounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug 7.